## NON-GISP REPORTING OF RESISTANCE

The American Public Health Laboratories and the 65 STD project areas were informally surveyed in 1999-2000 to identify cities or states that routinely performed antimicrobial susceptibility testing of *N. gonorrhoeae* in 1999. Information was not available on 45 of the 65 project areas. In 1999, no testing outside of GISP occurred in Arkansas, Colorado, Connecticut, Delaware, Indiana, Kansas, Kentucky, Missouri, Nevada, Pennsylvania, Rhode Island, or San Francisco. Information on testing in 1999 was available for 8 sites (**Table 1**).

**Table 1** Non-GISP antimicrobial susceptibility testing of *N. gonorrhoeae* in 8 sites in 1999.

City or state	Total # isolates	Cip S	Cip I	Cip R	Spe S	Spe R	Cfx S	Cfx DS	Cro S	Cro DS	Azi S	Azi DS <sup>+</sup>
Hawaii	182	166	1	15	10	0	-	-	10	1	-	-
Massachusetts	319	317	0	2	23	0	-	-	319	0	-	-
Michigan	228	228*	0	0	-	-	228	0	228	0	-	-
Milwaukee	73	69	4	0	-	-	-	-	73	0	-	-
Minnesota	250	250	0	0	250	0	250	0	250	0	-	-
New Hampshire	16	15	1	0	15	0	-	-	16	0	-	-
New York City	1938	1937	1	0	1938	0	-	-	1938	0	-	-
Washington	468	468	1	0	469	0	469	0	469	0	469	0
Total	3475	3450	8	17	2705	0	947	0	3303	0	469	0

The testing methodology for all sites except Washington state was by disk diffusion; Washington used the agar dilution method.

Cip=ciprofloxacin; Spe=spectinomycin; Cfx=cefixime; Cro=ceftriaxone; Azi=azithromycin; S=susceptible; DS=decreased susceptibility; I=intermediate resistant; R=resistant.

For their assistance in gathering these data, we acknowledge and thank: Hawaii - Norman O'Connor; Massachusetts - Harvey George; Michigan - Barbara Robinson-Dunn; Milwaukee, WI - Ajaib Singh and M. Stephen Gradus; Minnesota - Timothy Naimi and John Hunt; New Hampshire - Peggy Sweeney; New York City, NY - Aziz Toma, George Williams, and Gladys Schlanger; Washington - Wil Whittington and Judith Hale.

<sup>&</sup>lt;sup>+</sup>For this table, AziDS is defined as an isolate with azithromycin MIC\$1.0 μg/ml.

<sup>\*</sup>Michigan tested all 228 isolates against ofloxacin, rather than against ciprofloxacin.